FDA Grants Priority Review for ABBVIE's BLA761460 (DECNUPAZ)
The FDA has granted priority review for ABBVIE's Biologics License Application for DECNUPAZ (BLA761460).
Asset / Drug
Drug and asset intelligence for DECNUPAZ with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Monoclonal Antibody
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.